In BRAF-mutated melanoma cells, the inhibition of NAMPT, using FK866 and GMX1778, or its genetic knock-down, reduced cancer cell proliferation, both in vitro and in vivo [179,212,214], highlighting NAMPT as an actionable target for melanoma patients with BRAF mutations [171] (Figure 2). Here, NAMPT is linked to melanoma.